Eisai will present five-year Clarity AD outcomes for lecanemab at CTAD in Boston, alongside real-world clinic data, pooled ARIA safety rates and an analysis comparing continued dosing against stopping once amyloid plaques clear. The agenda has shifted away from proving efficacy toward duration, patient selection, delivery route and earlier diagnosis. For cognitive longevity, the unresolved question is whether amyloid clearance translates into durable preservation of function over years rather than months.
Key Points
- Five-year Clarity AD follow-up among longest for approved anti-amyloid therapy
- Poster compares continued dosing versus stopping after plaque clearance
- Real-world ARIA rates pooled across multiple countries; blood biomarkers assessed
Longevity Analysis
Extended lifespan without preserved cognition delivers little, which places the duration of benefit from amyloid-lowering therapy at the center of healthspan planning. The questions now being asked — when treatment can be withdrawn, how long biomarker effects persist, whether blood tests shorten the interval to diagnosis — are questions of sustained practice rather than initial proof, and they determine whether a patient can realistically stay on a regimen for a decade. Equally relevant is the safety signal: brain swelling and microhemorrhage rates in routine care reflect how the vasculature and the brain's clearance and defense mechanisms respond to sustained immune-mediated plaque removal, and those rates will shape who is suitable for long-term treatment.
Original published by Longevity.Technology, by Kyle Umipig.